Glaukos Corp

Glaukos Corp (GKOS)

$57.02

+1.39

(+2.5%)

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Glaukos Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 71.22M → 73.89M (in $), with an average increase of 3.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -27.57M → -34.62M (in $), with an average decrease of 12.1% per quarter

Performance

  • $55.35
    $57.16
    $57.02
    downward going graph

    2.93%

    Downside

    Day's Volatility :3.16%

    Upside

    0.24%

    downward going graph
  • $39.51
    $61.01
    $57.02
    downward going graph

    30.71%

    Downside

    52 Weeks Volatility :35.24%

    Upside

    6.54%

    downward going graph

Returns

PeriodGlaukos CorpSector (Health Care)Index (Russel 2000)
3 Months
17.79%
-0.3%
-6.7%
6 Months
19.45%
-8.8%
-6.2%
1 Year
36.25%
-4.2%
-5.1%
3 Years
37.73%
23.0%
26.9%

Highlights

Market Capitalization
2.7B
Book Value
$10.61
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.82
PEG Ratio
1.64
Wall Street Target Price
58.44
Profit Margin
-48.15%
Operating Margin TTM
-39.82%
Return On Assets TTM
-7.11%
Return On Equity TTM
-25.17%
Revenue TTM
289.1M
Revenue Per Share TTM
6.07
Quarterly Revenue Growth YOY
9.2%
Gross Profit TTM
213.9M
EBITDA
-82.8M
Diluted Eps TTM
-2.82
Quarterly Earnings Growth YOY
18.96
EPS Estimate Current Year
-2.26
EPS Estimate Next Year
-1.85
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
-0.57

Analyst Recommendation

Buy
    61%Buy
    38%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Glaukos Corp(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
7
7
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2.49%

Current $57.02
Target $58.44

Company Financials

FY17Y/Y Change
Revenue
159.3M
↑ 39.21%
Net Income
-92.0K
↓ 102.03%
Net Profit Margin
-0.06%
↓ 4.01%
FY18Y/Y Change
Revenue
181.3M
↑ 13.83%
Net Income
-13.0M
↑ 13977.17%
Net Profit Margin
-7.14%
↓ 7.08%
FY19Y/Y Change
Revenue
237.0M
↑ 30.73%
Net Income
15.4M
↓ 219.1%
Net Profit Margin
6.51%
↑ 13.65%
FY20Y/Y Change
Revenue
225.0M
↓ 5.07%
Net Income
-120.3M
↓ 880.26%
Net Profit Margin
-53.5%
↓ 60.01%
FY21Y/Y Change
Revenue
294.0M
↑ 30.7%
Net Income
-49.6M
↓ 58.79%
Net Profit Margin
-16.87%
↑ 36.63%
FY22Y/Y Change
Revenue
282.9M
↓ 3.79%
Net Income
-99.2M
↑ 100.02%
Net Profit Margin
-35.07%
↓ 18.2%
Q4 FY21Q/Q Change
Revenue
73.2M
↓ 1.97%
Net Income
-21.9M
↓ 451.08%
Net Profit Margin
-29.86%
↓ 38.2%
Q1 FY22Q/Q Change
Revenue
67.7M
↓ 7.59%
Net Income
5.4M
↓ 124.58%
Net Profit Margin
7.94%
↑ 37.8%
Q2 FY22Q/Q Change
Revenue
72.7M
↑ 7.39%
Net Income
-45.5M
↓ 946.87%
Net Profit Margin
-62.65%
↓ 70.59%
Q3 FY22Q/Q Change
Revenue
71.3M
↓ 1.95%
Net Income
-27.6M
↓ 39.44%
Net Profit Margin
-38.69%
↑ 23.96%
Q4 FY22Q/Q Change
Revenue
71.2M
↓ 0.06%
Net Income
-31.5M
↑ 14.08%
Net Profit Margin
-44.17%
↓ 5.48%
Q1 FY23Q/Q Change
Revenue
73.9M
↑ 3.75%
Net Income
-34.6M
↑ 10.06%
Net Profit Margin
-46.86%
↓ 2.69%
FY17Y/Y Change
Total Assets
165.8M
↑ 23.42%
Total Liabilities
27.6M
↑ 61.63%
FY18Y/Y Change
Total Assets
207.0M
↑ 24.8%
Total Liabilities
33.1M
↑ 19.82%
FY19Y/Y Change
Total Assets
818.4M
↑ 295.42%
Total Liabilities
145.1M
↑ 338.32%
FY20Y/Y Change
Total Assets
1.0B
↑ 22.86%
Total Liabilities
338.1M
↑ 132.93%
FY21Y/Y Change
Total Assets
1.0B
↑ 4.4%
Total Liabilities
462.5M
↑ 36.83%
FY22Y/Y Change
Total Assets
1.0B
↓ 4.51%
Total Liabilities
472.4M
↑ 2.13%
Q4 FY21Q/Q Change
Total Assets
1.0B
↓ 1.36%
Total Liabilities
462.5M
↓ 0.12%
Q1 FY22Q/Q Change
Total Assets
1.1B
↑ 0.23%
Total Liabilities
454.5M
↓ 1.74%
Q2 FY22Q/Q Change
Total Assets
1.0B
↓ 1.98%
Total Liabilities
468.8M
↑ 3.15%
Q3 FY22Q/Q Change
Total Assets
1.0B
↓ 2.21%
Total Liabilities
459.9M
↓ 1.9%
Q4 FY22Q/Q Change
Total Assets
1.0B
↓ 0.6%
Total Liabilities
472.4M
↑ 2.71%
Q1 FY23Q/Q Change
Total Assets
972.6M
↓ 2.97%
Total Liabilities
464.1M
↓ 1.76%
FY17Y/Y Change
Operating Cash Flow
25.5M
↑ 107.23%
Investing Cash Flow
-11.7M
↓ 55.1%
Financing Cash Flow
4.7M
↓ 384.23%
FY18Y/Y Change
Operating Cash Flow
18.9M
↓ 26.05%
Investing Cash Flow
-26.4M
↑ 125.12%
Financing Cash Flow
21.6M
↑ 362.31%
FY19Y/Y Change
Operating Cash Flow
-369.0K
↓ 101.96%
Investing Cash Flow
43.4M
↓ 264.49%
Financing Cash Flow
-9.6M
↓ 144.7%
FY20Y/Y Change
Operating Cash Flow
-23.0M
↑ 6129.81%
Investing Cash Flow
-205.1M
↓ 572.21%
Financing Cash Flow
262.5M
↓ 2822.05%
FY21Y/Y Change
Operating Cash Flow
24.7M
↓ 207.48%
Investing Cash Flow
-58.2M
↓ 71.6%
Financing Cash Flow
39.3M
↓ 85.05%
FY22Y/Y Change
Operating Cash Flow
-33.1M
↓ 233.9%
Investing Cash Flow
44.8M
↓ 176.9%
Financing Cash Flow
6.3M
↓ 84.08%
Q4 FY21Q/Q Change
Operating Cash Flow
-4.7M
↓ 126.14%
Investing Cash Flow
-8.9M
↓ 65.96%
Financing Cash Flow
1.6M
↓ 58.18%
Q1 FY22Q/Q Change
Operating Cash Flow
9.8M
↓ 310.15%
Investing Cash Flow
-5.9M
↓ 33.53%
Financing Cash Flow
1.4M
↓ 12.8%
Q2 FY22Q/Q Change
Operating Cash Flow
-12.2M
↓ 224.88%
Investing Cash Flow
9.6M
↓ 263.3%
Financing Cash Flow
106.0K
↓ 92.48%
Q3 FY22Q/Q Change
Operating Cash Flow
-26.5M
↑ 117.23%
Investing Cash Flow
24.4M
↑ 153.28%
Financing Cash Flow
4.2M
↑ 3867.92%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.1M
↓ 84.4%
Investing Cash Flow
16.7M
↓ 31.72%
Financing Cash Flow
529.0K
↓ 87.42%
Q1 FY23Q/Q Change
Operating Cash Flow
-30.8M
↑ 643.81%
Investing Cash Flow
-13.8M
↓ 183.05%
Financing Cash Flow
1.2M
↑ 117.77%

Technicals Summary

Sell

Neutral

Buy

Glaukos Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Glaukos Corp
Glaukos Corp
17.36%
19.45%
36.25%
37.73%
47.29%
Stryker Corporation
Stryker Corporation
-9.47%
16.08%
15.77%
37.64%
56.01%
Boston Scientific Corp.
Boston Scientific Corp.
-4.37%
11.53%
23.12%
34.64%
66.14%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.01%
5.39%
-19.28%
9.61%
77.87%
Abbott Laboratories
Abbott Laboratories
-8.46%
-5.46%
-13.41%
9.35%
65.3%
Medtronic PLC
Medtronic PLC
-9.02%
4.38%
-17.62%
-15.04%
-4.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Glaukos Corp
Glaukos Corp
NA
NA
1.64
-2.26
-0.25
-0.07
0.0
10.61
Stryker Corporation
Stryker Corporation
39.68
39.68
2.85
10.16
0.16
0.06
0.01
44.51
Boston Scientific Corp.
Boston Scientific Corp.
88.03
88.03
2.53
1.95
0.05
0.04
0.0
12.42
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
33.89
33.89
3.07
2.55
0.25
0.13
0.0
9.87
Abbott Laboratories
Abbott Laboratories
31.27
31.27
18.76
4.4
0.16
0.06
0.02
21.28
Medtronic PLC
Medtronic PLC
28.89
28.89
3.04
5.28
0.07
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Glaukos Corp
Glaukos Corp
Buy
$2.7B
47.29%
NA
-48.15%
Stryker Corporation
Stryker Corporation
Buy
$103.5B
56.01%
39.68
13.86%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$73.4B
66.14%
88.03
6.92%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$49.7B
77.87%
33.89
27.07%
Abbott Laboratories
Abbott Laboratories
Buy
$178.9B
65.3%
31.27
13.98%
Medtronic PLC
Medtronic PLC
Buy
$108.4B
-4.43%
28.89
12.03%

Institutional Holdings

  • BlackRock Inc

    16.19%
  • Vanguard Group Inc

    11.04%
  • Wellington Management Company LLP

    9.12%
  • Brown Capital Management, LLC

    6.04%
  • Artisan Partners Limited Partnership

    3.90%
  • State Street Corporation

    3.64%

Corporate Announcements

  • Glaukos Corp Earnings

    Glaukos Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Organization
Glaukos Corp
Employees
783
CEO
Mr. Thomas William Burns
Industry
Health Technology

FAQs